Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12440365 | 1.00 | KDM4E (0.40) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL15312742 | 1.00 | KDM4E (0.40) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL13809021 | 0.78 | GAA (0.42) | — | |
| SCHEMBL26105496 | 0.78 | DDB1 (0.41) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL5939108 | 0.75 | GPR119 (0.43) | KDM4EMAPTTHRBHSD17B10 | |
| SCHEMBL23373610 | 0.73 | GPR119 (0.41) | KDM4EMAPTTHRBHSD17B10 | |
| SCHEMBL5937755 | 0.73 | GPR119 (0.41) | KDM4EMAPTTHRBHSD17B10 | |
| SCHEMBL927569 | 0.72 | HSD17B10 (0.39) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL3336534 | 0.72 | HSD17B10 (0.39) | KDM4EMAPTTHRBDDB1CRBN | |
| SCHEMBL3338925 | 0.72 | HSD17B10 (0.39) | KDM4EMAPTTHRBDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8877961-B2 | Bridged monobactam intermediates | BASILEA PHARMACEUTICA AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20130274503-A1 | PROCESS FOR THE MANUFACTURE OF BRIDGED MONOBACTAM INTERMEDIATES | BASILEA PHARMACEUTICA AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-8450477-B2 | Process for the manufacture of bridged monobactam intermediates | Basilea Pharmaceutica A.G. (CH) | 2013-05-28 | — | — | US | disclosed |
| US-20110178291-A1 | Process for the manufacture of bridged monobactam intermediates | Basilea Pharmacuetica AG | 2011-07-21 | — | — | US | disclosed |
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | BASILEA PHARMACEUTICA AG | 2010-12-02 | — | — | US | disclosed |
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | BASILEA PHARMACEUTICA AG | 2010-12-02 | — | — | US | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| WO-2009071638-A2 | PROCESS FOR THE PREPARATION OF 2-(PRIMARY/SECONDARY AMINO)HYDROCARBYL)- CARBAMOYL-7-OXO-2,6-DIAZA-BICYCLO[3.2.0.]HEPTANE-6-SULFONIC ACID DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008039420-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274503-A1 | PROCESS FOR THE MANUFACTURE OF BRIDGED MONOBACTAM INTERMEDIATES | COASY, ACMSD, BPGM | KDM4E 2134/4885MAPT 1778/4885THRB 3775/4885 |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | KDM4E 1074/4885MAPT 3122/4885THRB 442/4885 |
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, SI, MGAM2 | KDM4E 2398/4885MAPT 4288/4885THRB 1179/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | KDM4E 1074/4885MAPT 3122/4885THRB 442/4885 |
| US-20110178291-A1 | Process for the manufacture of bridged monobactam intermediates | C1S, CCNB1, C9 | KDM4E 1891/4885MAPT 2491/4885THRB 3939/4885 |
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | C9, THOC2, ODC1 | KDM4E 1729/4885MAPT 4205/4885THRB 750/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | KDM4E 1140/4885MAPT 3096/4885THRB 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.